Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Electroanatomical Mapping of the Urinary Bladder.

Farag F, Koens M, Tijssen M, Jong Sd, Fabius T, Tromp J, Breda Hv, Smeets J, Feitz W, Heesakkers J.

Int Neurourol J. 2016 Jun;20(2):164-7. doi: 10.5213/inj.1630504.252. Epub 2016 Jun 24.

2.

The immunostimulatory activity of unmethylated and methylated CpG oligodeoxynucleotide is dependent on their ability to colocalize with TLR9 in late endosomes.

de Jong SD, Basha G, Wilson KD, Kazem M, Cullis P, Jefferies W, Tam Y.

J Immunol. 2010 Jun 1;184(11):6092-102. doi: 10.4049/jimmunol.0802442. Epub 2010 Apr 28.

3.

Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles.

Chikh G, de Jong SD, Sekirov L, Raney SG, Kazem M, Wilson KD, Cullis PR, Dutz JP, Tam YK.

Int Immunol. 2009 Jul;21(7):757-67. doi: 10.1093/intimm/dxp044. Epub 2009 Jun 5.

PMID:
19502586
4.

Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy.

Wilson KD, de Jong SD, Tam YK.

Adv Drug Deliv Rev. 2009 Mar 28;61(3):233-42. doi: 10.1016/j.addr.2008.12.014. Epub 2009 Feb 13. Review.

PMID:
19232375
5.

The combination of stabilized plasmid lipid particles and lipid nanoparticle encapsulated CpG containing oligodeoxynucleotides as a systemic genetic vaccine.

Wilson KD, de Jong SD, Kazem M, Lall R, Hope MJ, Cullis PR, Tam YK.

J Gene Med. 2009 Jan;11(1):14-25. doi: 10.1002/jgm.1267.

PMID:
19003796
6.

The effect of circulation lifetime and drug-to-lipid ratio of intravenously administered lipid nanoparticles on the biodistribution and immunostimulatory activity of encapsulated CpG-ODN.

Raney SG, Wilson KD, Sekirov L, Chikh G, de Jong SD, Cullis PR, Tam YK.

J Drug Target. 2008 Aug;16(7):564-77. doi: 10.1080/10611860802228756.

PMID:
18686126

Supplemental Content

Support Center